We are live on ! Find out more
PLRX icon

Pliant Therapeutics
PLRX

76 hedge funds and large institutions have $1.21B invested in Pliant Therapeutics in 2021 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 29 increasing their positions, 13 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

375% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 4

123% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 13

86% more capital invested

Capital invested by funds: $648M → $1.21B (+$560M)

25% more funds holding

Funds holding: 61 → 76 (+15)

5.58% more ownership

Funds ownership: 80.37% → 85.95% (+5.6%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
76
Holders Change
+15
Holders Change %
+24.59%
% of All Funds
1.33%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
19
Increased
29
Reduced
13
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BlackRock
BlackRock
New York
+$26.6M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$19.3M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$6.95M
4
State Street
State Street
Massachusetts
+$6.47M
5
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$4.47M

Top Sellers

1
EAM
Eventide Asset Management
Massachusetts
-$11.9M
2
RG
Redmile Group
California
-$5.88M
3
LGM
Logos Global Management
California
-$1.74M
4
CA
CHI Advisors
New York
-$974K
5
PCM
Pentwater Capital Management
Florida
-$341K
Name Holding Trade Value Shares
Change 		Change in
Stake
TGI
1
TRV GP III
Massachusetts
$230M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$211M +$1.25M +38,572 +0.7%
RG
3
Redmile Group
California
$126M -$5.88M -181,183 -5%
EAM
4
Eventide Asset Management
Massachusetts
$97.2M -$11.9M -366,233 -13%
CA
5
CHI Advisors
New York
$91.4M -$974K -30,004 -1%
TGI
6
TRV GP IV
Massachusetts
$83.9M – – –
BlackRock
7
BlackRock
New York
$65.9M +$26.6M +819,249 +96%
Citadel Advisors
8
Citadel Advisors
Florida
$48.1M -$327K -10,078 -0.8%
Vanguard Group
9
Vanguard Group
Pennsylvania
$43.4M +$19.3M +595,726 +118%
FCM
10
Farallon Capital Management
California
$30.1M – – –
CAM
11
Cormorant Asset Management
Massachusetts
$24M – – –
HMC
12
Harvard Management Company
Massachusetts
$22.1M – – –
Bessemer Group
13
Bessemer Group
New Jersey
$21.1M – – –
State Street
14
State Street
Massachusetts
$15M +$6.47M +199,258 +110%
Franklin Resources
15
Franklin Resources
California
$13.8M – – –
Lord, Abbett & Co
16
Lord, Abbett & Co
New Jersey
$12.9M +$4.47M +137,690 +73%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$11.1M +$4.33M +133,331 +90%
Northern Trust
18
Northern Trust
Illinois
$8.73M +$3.27M +100,556 +83%
T. Rowe Price Associates
19
T. Rowe Price Associates
Maryland
$8.42M +$6.95M +214,157 New
Bank of New York Mellon
20
Bank of New York Mellon
New York
$6.92M +$2.65M +81,497 +86%
IC
21
Ikarian Capital
Texas
$4.28M +$3.53M +108,700 New
Charles Schwab
22
Charles Schwab
California
$3.68M +$960K +29,576 +46%
N
23
Nuveen
North Carolina
$3.16M +$1.86M +57,172 +247%
D.E. Shaw & Co
24
D.E. Shaw & Co
New York
$3M +$2.48M +76,347 New
Millennium Management
25
Millennium Management
New York
$2.49M +$1.03M +31,570 +99%
1
2 3 4

PLRX Hedge Fund Activity: Q1 2021 in Review

76 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q1 2021, worth a combined $1.21B — up 86% from $648M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new PLRX positions and 4 closed out — a net gain of 15 holders — while 29 added to existing stakes and 13 trimmed.

The largest buyer was BlackRock, adding an estimated $26.6M. The largest seller was Eventide Asset Management, cutting an estimated $11.9M.

  • 76 institutional investors held Pliant Therapeutics (PLRX) as of Q1 2021, up from 61 in Q4 2020.
  • Funds reported $1.21B of Pliant Therapeutics stock for Q1 2021, up 86% quarter-over-quarter.
  • 19 funds opened new Pliant Therapeutics positions in Q1 2021 and 4 closed out, a net change of +15 holders.
  • The largest Pliant Therapeutics buyer in Q1 2021 was BlackRock, an estimated $26.6M added.
  • The largest Pliant Therapeutics seller in Q1 2021 was Eventide Asset Management, an estimated $11.9M sold.

Based on aggregated 13F filings for Q1 2021.